CN101759683A - 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 - Google Patents
二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 Download PDFInfo
- Publication number
- CN101759683A CN101759683A CN200810176591A CN200810176591A CN101759683A CN 101759683 A CN101759683 A CN 101759683A CN 200810176591 A CN200810176591 A CN 200810176591A CN 200810176591 A CN200810176591 A CN 200810176591A CN 101759683 A CN101759683 A CN 101759683A
- Authority
- CN
- China
- Prior art keywords
- heterocyclylalkyl
- alkyl
- cycloalkyl
- thiazolinyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (18)
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101765912A CN101759683B (zh) | 2008-12-25 | 2008-12-25 | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 |
KR1020117017286A KR101612115B1 (ko) | 2008-12-25 | 2009-12-24 | 디하이드로인덴 아미드 화합물의 제조 방법, 그 화합물을 포함하는 약학적 조성물 및 단백질 키나아제 억제제로의 용도 |
CA2748289A CA2748289C (en) | 2008-12-25 | 2009-12-24 | Preparation method of dihydroindene amide compounds,their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor |
BRPI0923728A BRPI0923728A2 (pt) | 2008-12-25 | 2009-12-24 | "método de preparação de compostos de di-hidroindeno amida, suas composições farmacêuticas contendo esses compostos e uso como inibidor de proteína quinase". |
UAA201107736A UA106057C2 (uk) | 2008-12-25 | 2009-12-24 | Спосіб одержання сполук дигідроінденаміду, фармацевтична композиція, що містить дані сполуки, та їх застосування як інгібітора протеїнкінази |
EP09834119.1A EP2385035B1 (en) | 2008-12-25 | 2009-12-24 | Preparation method of dihydroindene amide compounds their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor |
JP2011542656A JP5707335B2 (ja) | 2008-12-25 | 2009-12-24 | ジヒドロインデンアミド化合物の製造方法、それらの化合物を含有する医薬組成物、及びプロテインキナーゼ阻害剤としての使用 |
PCT/CN2009/076006 WO2010072166A1 (zh) | 2008-12-25 | 2009-12-24 | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 |
US13/141,651 US8703771B2 (en) | 2008-12-25 | 2009-12-24 | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor |
ES09834119.1T ES2502941T3 (es) | 2008-12-25 | 2009-12-24 | Método de preparación de compuestos de amida de dihidroindeno, las composiciones farmacéuticas que contienen dichos compuestos y el uso como inhibidor de proteína quinasas |
PL09834119T PL2385035T3 (pl) | 2008-12-25 | 2009-12-24 | Sposób wytwarzania związków dihydroindenoamidowych, ich kompozycje farmaceutyczne oraz zastosowanie jako inhibitorów kinaz białkowych |
RU2011125376/04A RU2528408C2 (ru) | 2008-12-25 | 2009-12-24 | Сп0соб получения соединений дигидроинденамида, фармацевтические композии, содержащие данные соединение и их применение в качестве ингибитора протеинкиназы |
NZ593295A NZ593295A (en) | 2008-12-25 | 2009-12-24 | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor |
CN2009801031146A CN101925572B (zh) | 2008-12-25 | 2009-12-24 | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 |
MX2011006724A MX2011006724A (es) | 2008-12-25 | 2009-12-24 | Metodo de preparacion de compuestos de amidas de dihidroindeno, sus composiciones farmaceuticas que contienen compuestos de las mismas y su uso como inhibidor de la proteina quinasa. |
AU2009329640A AU2009329640B2 (en) | 2008-12-25 | 2009-12-24 | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor |
IL213141A IL213141A (en) | 2008-12-25 | 2011-05-25 | Dihydroindane amides for use in regulating protein kinase activity |
ZA2011/04523A ZA201104523B (en) | 2008-12-25 | 2011-06-20 | Preparation method of dihydroindene amide compounds,their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor |
HK12103677.0A HK1163054A1 (zh) | 2008-12-25 | 2012-04-13 | 二氫化茚酰胺化合物製備方法、包含其的藥物組合物、及其作為蛋白激酶抑制劑的應用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101765912A CN101759683B (zh) | 2008-12-25 | 2008-12-25 | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101759683A true CN101759683A (zh) | 2010-06-30 |
CN101759683B CN101759683B (zh) | 2011-12-28 |
Family
ID=42286913
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101765912A Active CN101759683B (zh) | 2008-12-25 | 2008-12-25 | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 |
CN2009801031146A Active CN101925572B (zh) | 2008-12-25 | 2009-12-24 | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801031146A Active CN101925572B (zh) | 2008-12-25 | 2009-12-24 | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 |
Country Status (18)
Country | Link |
---|---|
US (1) | US8703771B2 (zh) |
EP (1) | EP2385035B1 (zh) |
JP (1) | JP5707335B2 (zh) |
KR (1) | KR101612115B1 (zh) |
CN (2) | CN101759683B (zh) |
AU (1) | AU2009329640B2 (zh) |
BR (1) | BRPI0923728A2 (zh) |
CA (1) | CA2748289C (zh) |
ES (1) | ES2502941T3 (zh) |
HK (1) | HK1163054A1 (zh) |
IL (1) | IL213141A (zh) |
MX (1) | MX2011006724A (zh) |
NZ (1) | NZ593295A (zh) |
PL (1) | PL2385035T3 (zh) |
RU (1) | RU2528408C2 (zh) |
UA (1) | UA106057C2 (zh) |
WO (1) | WO2010072166A1 (zh) |
ZA (1) | ZA201104523B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102295635A (zh) * | 2011-07-12 | 2011-12-28 | 辽宁大学 | 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用 |
CN102584830A (zh) * | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 二氢化茚酰胺化合物、其药物组合物及其用途 |
CN102603712A (zh) * | 2012-02-14 | 2012-07-25 | 陈烨 | S型和r型四氢化萘酰胺类抗肿瘤化合物和其药学上可接受的盐或前药及制备方法和应用 |
CN102807558A (zh) * | 2012-08-29 | 2012-12-05 | 浙江大德药业集团有限公司 | 作为蛋白激酶抑制剂的含氟二氢化茚酰胺类化合物 |
CN103006665A (zh) * | 2011-09-22 | 2013-04-03 | 北京美迪康信医药科技有限公司 | 一种药物组合物及其制剂和用途 |
CN103018190A (zh) * | 2011-09-22 | 2013-04-03 | 北京美迪康信医药科技有限公司 | 一种药物制剂及其溶出度测定方法 |
CN103006664A (zh) * | 2011-09-22 | 2013-04-03 | 北京美迪康信医药科技有限公司 | 一种具有酪氨酸蛋白激酶抑制作用的药物组合物 |
CN103370324A (zh) * | 2010-12-27 | 2013-10-23 | 孙树萍 | 作为蛋白激酶抑制剂的芳炔类衍生物及其医疗用途 |
CN104045632A (zh) * | 2014-06-03 | 2014-09-17 | 辽宁大学 | 抗肿瘤药物苯并二氢吡喃(噻喃)酰胺类化合物及其药学上可接受的盐及制备方法和应用 |
CN110833547A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药(集团)股份有限公司 | 吡唑并嘧啶衍生物在治疗类风湿关节炎的用途 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103018349B (zh) * | 2011-09-22 | 2015-04-08 | 北京美迪康信医药科技有限公司 | 一种二氢化茚酰胺化合物的检测分析方法 |
CN103083666B (zh) * | 2011-10-28 | 2016-02-10 | 北京美迪康信医药科技有限公司 | 一种药物组合物及其制剂和用途 |
CN103373984A (zh) * | 2012-04-24 | 2013-10-30 | 哈尔滨誉衡药业股份有限公司 | 一种二氢化茚酰胺化合物晶型、制备方法及其用途 |
EP3054936B1 (en) | 2013-10-10 | 2023-10-18 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors |
PL3057964T3 (pl) | 2013-10-14 | 2020-05-18 | Eisai R&D Management Co., Ltd. | Selektywnie podstawione związki chinolinowe |
MX363708B (es) | 2013-10-14 | 2019-03-29 | Eisai R&D Man Co Ltd | Compuestos de quinolina selectivamente sustituidos. |
KR20170012404A (ko) * | 2014-06-02 | 2017-02-02 | 씨에이치디아이 파운데이션, 인코포레이티드 | 히스톤 데아세틸라제 억제제 및 그것의 조성물 및 사용 방법 |
EP3601216B1 (en) | 2017-03-21 | 2023-10-25 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
JP2023509260A (ja) | 2019-08-14 | 2023-03-08 | インサイト・コーポレイション | Cdk2阻害剤としてのイミダゾリルピリミジニルアミン化合物 |
AR120184A1 (es) | 2019-10-11 | 2022-02-02 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
CN113350348B (zh) * | 2020-11-05 | 2022-03-01 | 东南大学 | 一种1-二苯甲基-4-甲基哌嗪类化合物在制备保护肠道屏障完整性药物中的应用 |
TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
CN114573591B (zh) * | 2022-04-16 | 2023-04-25 | 成都施贝康生物医药科技有限公司 | 一种取代的吡咯并嘧啶化合物及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
EP1388342A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
MXPA06012613A (es) * | 2004-05-07 | 2007-01-31 | Amgen Inc | Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer. |
CN1944398A (zh) * | 2005-01-11 | 2007-04-11 | 中国医学科学院药物研究所 | 新的苯甲酰胺类化合物及其制法和药物用途 |
-
2008
- 2008-12-25 CN CN2008101765912A patent/CN101759683B/zh active Active
-
2009
- 2009-12-24 US US13/141,651 patent/US8703771B2/en not_active Expired - Fee Related
- 2009-12-24 WO PCT/CN2009/076006 patent/WO2010072166A1/zh active Application Filing
- 2009-12-24 EP EP09834119.1A patent/EP2385035B1/en not_active Not-in-force
- 2009-12-24 MX MX2011006724A patent/MX2011006724A/es active IP Right Grant
- 2009-12-24 PL PL09834119T patent/PL2385035T3/pl unknown
- 2009-12-24 RU RU2011125376/04A patent/RU2528408C2/ru not_active IP Right Cessation
- 2009-12-24 NZ NZ593295A patent/NZ593295A/xx not_active IP Right Cessation
- 2009-12-24 JP JP2011542656A patent/JP5707335B2/ja not_active Expired - Fee Related
- 2009-12-24 ES ES09834119.1T patent/ES2502941T3/es active Active
- 2009-12-24 AU AU2009329640A patent/AU2009329640B2/en not_active Ceased
- 2009-12-24 KR KR1020117017286A patent/KR101612115B1/ko not_active IP Right Cessation
- 2009-12-24 UA UAA201107736A patent/UA106057C2/uk unknown
- 2009-12-24 BR BRPI0923728A patent/BRPI0923728A2/pt not_active IP Right Cessation
- 2009-12-24 CA CA2748289A patent/CA2748289C/en not_active Expired - Fee Related
- 2009-12-24 CN CN2009801031146A patent/CN101925572B/zh active Active
-
2011
- 2011-05-25 IL IL213141A patent/IL213141A/en not_active IP Right Cessation
- 2011-06-20 ZA ZA2011/04523A patent/ZA201104523B/en unknown
-
2012
- 2012-04-13 HK HK12103677.0A patent/HK1163054A1/zh not_active IP Right Cessation
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103370324B (zh) * | 2010-12-27 | 2016-05-18 | 孙树萍 | 作为蛋白激酶抑制剂的芳炔类衍生物及其医疗用途 |
CN103370324A (zh) * | 2010-12-27 | 2013-10-23 | 孙树萍 | 作为蛋白激酶抑制剂的芳炔类衍生物及其医疗用途 |
CN102295635A (zh) * | 2011-07-12 | 2011-12-28 | 辽宁大学 | 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用 |
CN102295635B (zh) * | 2011-07-12 | 2013-10-09 | 辽宁大学 | 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用 |
WO2013007184A1 (zh) * | 2011-07-12 | 2013-01-17 | Chen Ye | 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用 |
CN103018190A (zh) * | 2011-09-22 | 2013-04-03 | 北京美迪康信医药科技有限公司 | 一种药物制剂及其溶出度测定方法 |
CN103006665A (zh) * | 2011-09-22 | 2013-04-03 | 北京美迪康信医药科技有限公司 | 一种药物组合物及其制剂和用途 |
CN103006664A (zh) * | 2011-09-22 | 2013-04-03 | 北京美迪康信医药科技有限公司 | 一种具有酪氨酸蛋白激酶抑制作用的药物组合物 |
CN103006664B (zh) * | 2011-09-22 | 2016-02-10 | 北京美迪康信医药科技有限公司 | 一种具有酪氨酸蛋白激酶抑制作用的药物组合物 |
CN103018190B (zh) * | 2011-09-22 | 2016-02-10 | 北京美迪康信医药科技有限公司 | 一种药物制剂及其溶出度测定方法 |
CN102584830A (zh) * | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 二氢化茚酰胺化合物、其药物组合物及其用途 |
CN102603712A (zh) * | 2012-02-14 | 2012-07-25 | 陈烨 | S型和r型四氢化萘酰胺类抗肿瘤化合物和其药学上可接受的盐或前药及制备方法和应用 |
CN102807558A (zh) * | 2012-08-29 | 2012-12-05 | 浙江大德药业集团有限公司 | 作为蛋白激酶抑制剂的含氟二氢化茚酰胺类化合物 |
CN104045632A (zh) * | 2014-06-03 | 2014-09-17 | 辽宁大学 | 抗肿瘤药物苯并二氢吡喃(噻喃)酰胺类化合物及其药学上可接受的盐及制备方法和应用 |
CN110833547A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药(集团)股份有限公司 | 吡唑并嘧啶衍生物在治疗类风湿关节炎的用途 |
Also Published As
Publication number | Publication date |
---|---|
CA2748289A1 (en) | 2010-07-01 |
EP2385035A4 (en) | 2013-07-10 |
CA2748289C (en) | 2015-08-18 |
ES2502941T3 (es) | 2014-10-06 |
JP2012513956A (ja) | 2012-06-21 |
HK1163054A1 (zh) | 2012-09-07 |
MX2011006724A (es) | 2011-07-13 |
EP2385035A1 (en) | 2011-11-09 |
CN101925572B (zh) | 2011-12-28 |
BRPI0923728A2 (pt) | 2019-09-24 |
IL213141A0 (en) | 2011-07-31 |
US8703771B2 (en) | 2014-04-22 |
CN101925572A (zh) | 2010-12-22 |
KR20110099332A (ko) | 2011-09-07 |
JP5707335B2 (ja) | 2015-04-30 |
KR101612115B1 (ko) | 2016-04-12 |
US20110319420A1 (en) | 2011-12-29 |
ZA201104523B (en) | 2012-03-28 |
AU2009329640A1 (en) | 2011-06-30 |
UA106057C2 (uk) | 2014-07-25 |
EP2385035B1 (en) | 2014-06-25 |
WO2010072166A1 (zh) | 2010-07-01 |
RU2528408C2 (ru) | 2014-09-20 |
RU2011125376A (ru) | 2013-01-27 |
NZ593295A (en) | 2012-12-21 |
CN101759683B (zh) | 2011-12-28 |
IL213141A (en) | 2014-12-31 |
AU2009329640B2 (en) | 2015-06-25 |
PL2385035T3 (pl) | 2014-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101759683B (zh) | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 | |
CN102971317B (zh) | 四氢-吡啶并-嘧啶衍生物 | |
CN103153980B (zh) | 吡唑并苯基苯磺酰胺化合物的衍生物及其作为抗肿瘤药的用途 | |
CN101821255A (zh) | 作为pi3k抑制剂的2-吗啉-4-基-嘧啶类化合物 | |
JP6896701B2 (ja) | イミダゾリルアミド誘導体 | |
CN102295635B (zh) | 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用 | |
CN104507933A (zh) | 氨基喹唑啉和吡啶并嘧啶衍生物 | |
CN103483345A (zh) | Pi3k 激酶抑制剂、包含其的药物组合物及其应用 | |
CN106478605A (zh) | 嘧啶类化合物、其制备方法和医药用途 | |
WO2021197467A1 (zh) | 多靶点的抗肿瘤化合物及其制备方法和应用 | |
CN103130775B (zh) | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 | |
CN103102352B (zh) | 酪氨酸激酶抑制剂吲哚满酮衍生物 | |
JP6913955B2 (ja) | PI3K/mTOR阻害剤としての溶融キノリン化合物 | |
CA2958741A1 (en) | Quinazoline derivatives | |
CN110028509A (zh) | 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途 | |
WO2014086102A1 (zh) | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 | |
CN103130791B (zh) | 一种新型苯甲酰胺类化合物 | |
CN111718325A (zh) | 一种2,4,5-取代嘧啶类化合物及其制备方法和应用 | |
WO2022237825A1 (zh) | 具有egfr抑制活性的氮杂芳基衍生物、其制备方法和应用 | |
CN109867661A (zh) | 调节wnt信号通路的酰胺类化合物及其用途 | |
CN102807558A (zh) | 作为蛋白激酶抑制剂的含氟二氢化茚酰胺类化合物 | |
CN105541792A (zh) | 多环类pi3k抑制剂 | |
CN102827160A (zh) | PI3K或PI3K/m-TOR通路抑制剂及其在药学中的用途 | |
CN112384506B (zh) | 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HARBIN GLORIA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING MEIDISAI MEDICINE TECHNOLOGY CO., LTD. Effective date: 20101206 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100085 ROOM 416, OFFICE BUILDING 2, NO.18, ANNINGZHUANG EAST ROAD, QINGHE, HAIDIAN DISTRICT, BEIJING TO: 150025 NO.29, BEIJING ROAD, LIMIN ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, HARBIN CITY, HEILONGJIANG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20101206 Address after: 150025, 29 Beijing Road, Limin economic and Technological Development Zone, Heilongjiang, Harbin Applicant after: Harbin Gloria Pharmaceuticals Co., Ltd. Address before: 100085, Beijing, Haidian District Qinghe Anning East Road No. 2 office building 416, room 18 Applicant before: Beijing Medesignpharma Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: BEIJING MEDCONXIN PHARMACEUTICAL TECHNOLOGY CO., L |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20111020 Address after: 150025, 29 Beijing Road, Limin economic and Technological Development Zone, Heilongjiang, Harbin Applicant after: Harbin Gloria Pharmaceuticals Co., Ltd. Co-applicant after: Beijing Medconxin Pharmaceutical Technology Co., Ltd. Address before: 150025, 29 Beijing Road, Limin economic and Technological Development Zone, Heilongjiang, Harbin Applicant before: Harbin Gloria Pharmaceuticals Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170622 Address after: 150025, No. 29, Beijing Road, Limin economic and Technological Development Zone, Hulan District, Heilongjiang, Harbin Patentee after: Harbin Yu Heng Pharmaceutical Co., Ltd. Address before: 150025, 29 Beijing Road, Limin economic and Technological Development Zone, Heilongjiang, Harbin Co-patentee before: Beijing Medconxin Pharmaceutical Technology Co., Ltd. Patentee before: Harbin Gloria Pharmaceuticals Co., Ltd. |
|
TR01 | Transfer of patent right |